AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00177164 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Injectable Risperidone (Consta) or oral antipsychotic
Description: Injectable Risperidone (Consta) from 12.5 to 50 mg q 2 weeks~Oral antipsychotic agents, olanzapine, quetiapine, ziprasidone, aripiprazole in doses approved in the US for bipolar disorder
Study NCT04552665 — intervention group
Intervention type: DEVICE
Intervention: KODEX-EPD system
Description: To evaluate the performance of the KODEX-EPD system and collect procedural data and medical images for Philips' internal research and development activities (R\&D)
Study NCT01080703 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Lower extremity resistance exercises and aerobic exercises 3 times a week in 10 week pulmonary rehabilitation program prior to lung transplant.
Study NCT03330990 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Entrectinib
Description: 600 mg oral capsule (fasted and fed)
Study NCT03330990 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Midazolam Hydrochloride
Description: 2 mg oral syrup (fasted)
Study NCT01283503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120
Study NCT02878018 — intervention group
Intervention type: DRUG
Intervention: Qi-Ji Shen-Kang formula; Zhu-Bai formula; Yu-Shen formula
Description: Qi-Ji Shen-Kang formula:15g of field thistle,10g of common edelweiss herb,10g of spreading hedyotis herb,10g ofYunnan manyleaf Paris rhizome,10g of hairyvein agrimonia herb,10g of the root bark of the tree peony,15g of root of red rooted salvia, and 15g ofmembranous mikvetch root.Zhu-Bai formula:10g of glabrous greenbrier rhizome,5g of Chinese atractylodes rhizome,10g of amur corktree bark,10g of common edelweiss her),10g of field thistle,10g of lalang grass rhizome,10g of garden burnet root,5g of longbract cattail pollen,5g of rehmanniae radix, and 5g of Chinese angelica root.Yu-Shen formula:15g of membranous mikvetch root,10g of heterophylla falsestarwort root,10g of field thistle,10g of cogongrass rhizome,10g of spreading hedyotis herb,10g of root of red rooted salvia,10g of fresh root of rehmannia,10g of Asian puccoon,10g of wormwoodlike motherwort herb,10g of common cockscomb inflorescence,10g of gordon euyale,10g of root bark of the tree peony, and 5g of licorice root.
Study NCT02878018 — intervention group
Intervention type: DRUG
Intervention: angiotensin-converting enzyme (ACE) inhibitor; adrenergic receptor binder (ARB); adrenal cortical hormone; Tripterygium wilfordii polyglycosidium; immunosuppressant
Description: prednisone at a dose of 1-1.5 mg/(kg·d) and Tripterygium wilfordii polyglycosidium at a dose of 1 mg/(kg·d). For each patient, the specific Western medicines used and their doses may be adjusted at the discretion of his or her physician, but the classes cannot be changed.
Study NCT01412281 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Virosomal influenza vaccine (AdImmune HA Antigen)
Description: Virosomal influenza vaccine (surface antigen, inactivated, virosome, using AdImmune HA Antigen) 2011/2012, with intramuscular administration, containing per 0.5 mL dose: 15 μg HA antigen of A/California/7/2009 (H1N1)-like virus; 15 μg HA antigen of A/Perth/16/2009 (H3N2)-like virus; 15 μg HA antigen of B/Brisbane/60/2008-like virus
Study NCT01412281 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Virosomal influenza vaccine (CSL HA Antigen)
Description: Virosomal influenza vaccine (surface antigen, inactivated, virosome, using CSL HA antigen) 2011/2012 with intramuscular administration, containing per 0.5 mL dose: 15 μg HA antigen of A/California/7/2009 (H1N1)-like virus; 15 μg HA antigen of A/Perth/16/2009 (H3N2)-like virus; 15 μg HA antigen of B/Brisbane/60/2008-like virus
Study NCT02374710 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ACL Reconstruction: Anterior Tunnel
Description: ACL reconstruction with anterior tibial tunnel placement in reference to a point measuring 35% of the anterior-posterior distance of the proximal tibia.
Study NCT02374710 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ACL Reconstruction: Posterior Tunnel
Description: ACL reconstruction with posterior tibial tunnel placement in reference to a point measuring 35% of the anterior-posterior distance of the proximal tibia.
Study NCT02213705 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INJECTION OF ALLOGENEIC MESENCHYMAL STEM CELLS
Study NCT02351700 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV Caldolor
Description: IV Caldolor (IV ibuprofen) intraoperatively and postoperatively
Study NCT02351700 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IV Placebo
Description: IV Placebo intraoperatively and postoperatively
Study NCT02044731 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active and Healthy Families
Description: A pediatric overweight/obesity intervention delivered through five bi-weekly family-based group sessions.
Study NCT02330939 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low fat- Low glycemic index meal
Study NCT02330939 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MUFA- Low glycemic index meal
Study NCT02330939 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SAFA- Low glycemic index meal
Study NCT02330939 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low fat- High glycemic index meal
Study NCT02330939 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MUFA- High glycemic index meal
Study NCT02330939 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SAFA- High glycemic index meal
Study NCT01174186 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: Tumor Necrosis Factor (TNF) alpha inhibitor given 40 mg subcutaneously every other week except the first time where 80 mg is given
Study NCT04796480 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: YOGURT
Description: Group 1 was given yogurt
Study NCT04796480 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: LACTOSE FREE FORMULA MILK
Description: Group 2 was given lactose free formula milk
Study NCT02849951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LT-02
Description: 12-weeks of 1.6 g BID delayed-release phosphatidylcholine (LT-02)
Study NCT02849951 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LT-02 Placebo
Description: 12-weeks of 0 g BID delayed-release phosphatidylcholine (LT-02) placebo
Study NCT05069480 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality-based training equipment.
Description: It is a functional upper extremity rehabilitation device to provide specific therapy with augmented feedback. The equipment facilitates intensive task-oriented upper extremity therapy after stroke, traumatic brain injury, or other neurological diseases and injuries. It combines adjustable arm support, with augmented feedback and a large 3D workspace that allows functional therapy exercises in a virtual reality environment.
Study NCT05069480 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional physical therapy program
Description: The traditional physical therapy program aimed for inhibition of spasticity, facilitation of muscle action, and improving the motor functions of the involved upper limbs.
Study NCT05069480 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional physical therapy program
Description: The traditional physical therapy program aimed for inhibition of spasticity, facilitation of muscle action, and improving the motor functions of the involved upper limbs.
Study NCT01943045 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NGM282
Study NCT01943045 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02241551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine/nab-paclitaxel
Description: three cycles of treatment in the gemcitabine/nab-paclitaxel
Study NCT02241551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFIRINOX
Description: 6 cycles in the mFOLFIRINOX
Study NCT00743535 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transobturatory correction of anterior defect plus TOT
Description: Longitudinal vaginal incision 1 cm far from esternal urethral meatus. Bladder dissecting and identification of ischiatic spines. Bilateral transobturator insertion of anterior mesh through high and low trans-obturatory approach. Mesh anchorage.~Small incision sites in the femoral/pelvic fold. Bilateral transobturator insertion of mesh by means of mono-use needle
Study NCT00743535 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transobturatory correction of anterior defect plus TVT
Description: Longitudinal vaginal incision 1 cm far from esternal urethral meatus. Bladder dissecting and identification of ischiatic spines. Bilateral transobturator insertion of anterior mesh through high and low trans-obturatory approach. Mesh anchorage.~Small incision sites at sovrapubic level. Bilateral retropubic insertion of mesh by means of mono-use needle.
Study NCT03417076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bexagliflozin
Description: Bexagliflozin tablets, 20 mg, and bexagliflozin by IV
Study NCT02730533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: Proton pump inhibitor
Study NCT02730533 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: No PPI treatment
Description: No PPI treatment before ESD procedure
Study NCT01961817 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Retromolar Vocal Cord Visualisation
Description: For easier insertion of the laryngoscope the head of the patient will be turned to the left site. Thereafter the blade (Miller) will be inserted into the mouth and pushed carefully as far as possible laterally to receive a direct view of the vocal cords. Then the performing anesthesiologist determine the Cormack \& Lehane score without and thereafter with a BURP (backward upward rightward pressure) maneuver.
Study NCT01961817 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Conventional Vocal Cord Visualisation
Description: The head of the patient will be positioned as usual. After 2 minutes oxygen insufflation the laryngoscope will be inserted laterally to push the tongue to the left side in order to release the sight to the vocal cords. Thereafter the anesthesiologist determines the Cormack \& Lehane score without and thereafter with performance of the BURP (backward upward rightward pressure) maneuver.
Study NCT02448160 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: alfapump
Description: Implantation of alfapump
Study NCT02448160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: salt-poor Human Albumin solution
Description: Patients implanted with an alfapump will receive intermittent salt-poor human albumin solution
Study NCT01438593 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intercerebral implantation of allogenic CD34+ stem cell
Description: Each patient will receive brain implant of approximately 5 million allogenic Umbilical cord blood CD34+ Stem Cell
Study NCT00830414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: medroxyprogesterone acetate
Description: IM Injection
Study NCT00830414 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: medroxyprogesterone acetate
Description: IM injection
Study NCT00840203 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rowasa® 4 gm/60 mL Rectal Enema
Description: 1 x 4 gm/60 mL, single-dose
Study NCT00840203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesalamine 4 gm/60 mL Rectal Enema
Description: 1 x 4 gm/60 mL, single-dose
Study NCT04362293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydroxyurea, azathioprine, alemtuzumab, thioptepa, low dose total body irradiation and sirolimus
Description: The conditioning regimen will consist of hydroxyurea (30mg/Kg) and azathioprine (3mg/Kg) by mouth daily from day -60 to day -8, alemtuzumab subcutaneously daily for 5 days (0.03mg/kg on Day -7, 0.1mg/kg on Day -6, 0.3mg/kg on days -5 to -3), thiotepa intravenously (10mg/Kg) on day -3 and low dose total body irradiation (TBI) 200 cGY on day -2 with gonadal shielding (if possible). The HSCT graft will be G-CSF mobilized PBSCs with minimum CD34+ of 5 x10\^6/kg recipient weight.~GVHD prophylaxis will be sirolimus with a loading dose 3 mg/m2 on day -1. Sirolimus dose will be adjusted to maintain a target trough level 5-15 ng/mL. Low dose donor lymphocyte infusions will begin on day +28 and continue till donor lymphocyte chimerism reaches at least 90% donor.
Study NCT04362293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydroxyurea, azathioprine, alemtuzumab, thiotepa, plerixafor, low dose total body irradiation, cyclophosphamide and sirolimus
Description: The conditioning regimen will consist of hydroxyurea (30mg/Kg) and azathioprine (3mg/Kg) by mouth daily from day -60 to day -8, alemtuzumab subcutaneously daily for 5 days (0.03mg/kg on Day -7, 0.1mg/kg on Day -6, 0.3mg/kg on days -5 to -3), thiotepa intravenously (10mg/Kg) on day -3, plerixafor (0.24mg/Kg) subcutaneously every 12 hours on days -3 and -2 and low dose total body irradiation (TBI) 200 cGY on days -2 and -1 with gonadal shielding (if possible). The HSCT graft will be G-CSF mobilized PBSCs with minimum CD34+ of 5 x10\^6/kg recipient weight.~GVHD prophylaxis will be cyclophosphamide (50mg/Kg) intravenously on days +3 and +4 and sirolimus with a loading dose 3 mg/m2 starting on day +5. Sirolimus dose will be adjusted to maintain a target trough level 5-15 ng/mL. Low dose donor lymphocyte infusions will begin on day +28 and continue till donor lymphocyte chimerism reaches at least 90% donor.
Study NCT03808376 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring System
Description: The Eversense® 180 CGM System
Study NCT04268615 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Covert Saccades and Virtual Reality
Description: During this intervention, patients will undergo head impulse testing while wearing virtual reality Headsets. During the head impulse tests the visual information will be modified in order to create a conflict between head rotation and rotation of the visual scene. Recording of head and eye movement will be done during these head impulses in order to verify if visual information modifies compensatory eye movements during head impulses.
Study NCT04268615 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Covert Saccades and Virtual Reality
Description: During this intervention, patients will undergo head impulse testing while wearing virtual reality Headsets. During the head impulse tests the visual information will be modified in order to create a conflict between head rotation and rotation of the visual scene. Recording of head and eye movement will be done during these head impulses in order to verify if visual information modifies compensatory eye movements during head impulses.
Study NCT04268615 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Actives versus passives Head Impulses
Description: Patients will undergo classic passive head rotation as well as active head rotation in order to compare latencies of covert saccades in both conditions.
Study NCT04268615 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Actives versus passives Head Impulses
Description: Patients will undergo classic passive head rotation as well as active head rotation in order to compare latencies of covert saccades in both conditions.
Study NCT04268615 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visually guided saccades
Description: Patients as well as healthy control subjects will undergo testing of visually guided saccades in different conditions (step, gap, overlap) in order to compare latencies of covert saccades between both groups.
Study NCT04268615 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Visually guided saccades
Description: Patients as well as healthy control subjects will undergo testing of visually guided saccades in different conditions (step, gap, overlap) in order to compare latencies of covert saccades between both groups.
Study NCT03849651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide is a nitrogen mustard derivative. It acts as an alkylating agent that causes cross-linking of DNA strands by binding with nucleic acids and other intracellular structures, thus interfering with the normal function of DNA.~intravenously (IV) once daily (QD) on day -9
Study NCT03849651 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine phosphate is a synthetic purine nucleoside analog. It acts by inhibiting DNA polymerase, ribonucleotide reductase and DNA primase by competing with the physiologic substrate, deoxyadenosine triphosphate, resulting in inhibition of DNA synthesis.~fludarabine phosphate IV QD on days -8 to -4
Study NCT03849651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: Thiotepa is a cell-cycle nonspecific polyfunctional alkylating agent.
Study NCT03849651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Melphalan, a derivative of nitrogen mustard, is a bifunctional alkylating agent. Melphalan is active against tumor cells that are actively dividing or at rest.~melphalan IV QD on days -2 to -1
Study NCT03849651 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: G-csf
Description: G-csf (granulocytic colony stimulating factor), is a biosynthetic hematopoietic agent that is made using recombinant DNA technology in cultures of Escherichia coli. G-CSF stimulates production, maturation and activation of neutrophils. In addition, endogenous G-CSF enhances certain functions of mature neutrophils, including phagocytosis, chemotaxis and antibody--dependent cellular cytotoxicity.
Study NCT03849651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: Mesna is a synthetic sulfhydryl (thiol) compound. Mesna contains free sulfhydryl groups that interact chemically with urotoxic metabolites of oxaza-phosphorine derivatives such as cyclophosphamide and ifosfamide. Following glomerular filtration, mesna disulfide is rapidly reduced in the renal tubules back to mesna, the active form of the drug.
Study NCT03849651 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CliniMACS
Description: Cells for infusion are prepared using the CliniMACS
Study NCT03849651 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ATG (rabbit)
Description: Anti-thymocyte globulin is a purified, pasteurized, gamma immune globulin, obtained by immunization of rabbits with human thymocytes.~rabbit anti-thymocyte globulin IV daily over 6 hours on days -5 to -3,
Study NCT03849651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Blinatumomab is a bispecific CD19-directed CD3 T-cell engager that mediates formation of a synapse between T cells and the CD19+ target cell, resulting in lysis of that CD19+ cell.Blinatumomab will be given to patients with a history of CD19+ malignancy as determined by St. Jude hematopathologist review of current and historical specimens and reports.~blinatumomab IV for 28 days beginning at least 1 week post-DLI
Study NCT03849651 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TCRα/β+
Description: IV on day 0 and may receive an additional dose on day 1
Study NCT03849651 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19+
Description: IV on day 0 and may receive an additional dose on day 1
Study NCT03849651 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD45RA-depleted DLI
Description: infusion IV
Study NCT04605211 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Mindfulness Meditation
Description: Complete online audio-based mindfulness meditation exercises
Study NCT04605211 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-Based Webinars
Description: Attend webinars
Study NCT04501848 — intervention group
Intervention type: PROCEDURE
Intervention: adenotonsillectomy
Description: adenotonsillectomy surgery
Study NCT02248051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CXA-10
Description: CXA-10 Injectable Emulsion is a sterile emulsion containing CXA-10 in a formulation containing soybean oil, medium chain triglycerides oil, egg phospholipids, sucrose, and disodium EDTA. CXA-10 Injectable Emulsion will be administered intravenously. The active emulsion will be diluted in a vehicle emulsion.
Study NCT03333551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F18 Florbetapir (amyvid) cardiac PET/CT imaging
Description: Patients with cardiac amyloidosis (AL) undergoing planned plasma cell directed chemotherapy will have F-18 florbetapir (amyvid) cardiac PET/CT imaging prior to starting chemotherapy and six months after onset of treatment.
Study NCT01844843 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TCD-10023 drug eluting stent
Description: Implantation of new drug eluting stent in coronary artery lesions
Study NCT01714622 — intervention group
Intervention type: PROCEDURE
Intervention: subtotal gastrectomy with gastroduodenostomy
Study NCT01714622 — intervention group
Intervention type: PROCEDURE
Intervention: subtotal gastrectomy with Roux-en-Y gastrojejunostomy,
Study NCT01714622 — intervention group
Intervention type: PROCEDURE
Intervention: total gastrectomy with Rou-en-Y esophagojejunostomy
Study NCT01943435 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NSAIDs; adjunctive analgesics; adjunctive anti-depressants
Description: Physician will administer these medications based upon the individual needs of each patient.